Cerebrolysin vs N-Acetyl Selank

Standardized mixture of neuropeptides derived from porcine brain proteins; mimics endogenous neurotrophic factors (BDNF, NGF, CNTF); promotes neurogenesis and synaptic plasticity

Cerebrolysin is a brain-derived polypeptide preparation derived from porcine cortical tissue, composed of low-molecular-weight neuropeptides and free amino acids that cross the blood-brain barrier and exert neurotrophic and neuroprotective effects. It is proposed to mimic endogenous neurotrophic factors, supporting neuronal survival, synaptic plasticity, and metabolic activity in damaged or degenerating brain tissue through multiple growth factor-like pathways. A Cochrane systematic review and multiple controlled clinical trials from Eastern European research groups have evaluated cerebrolysin for vascular dementia and stroke-related cognitive impairment, with mixed results that suggest potential benefit in specific post-stroke populations. Cerebrolysin is not FDA-approved; it is approved and widely used in Russia, Eastern Europe, and some Asian countries as a prescription neuroprotective treatment, and its evidence base reflects predominantly Eastern European clinical methodology with variable trial quality. Cerebrolysin price and access: Cerebrolysin is not available through standard US pharmacy channels; it is a prescription medication in the countries where it is approved (Russia, Eastern Europe, China, South Korea, and others) and is not FDA-approved. In markets where it is approved, cerebrolysin is administered intravenously in clinical settings — IV infusion courses of 10–20 sessions are the standard research and clinical protocol, with treatment costs varying significantly by country and clinic. Importation for personal use exists in a legal grey area in the United States; some wellness and peptide clinics may offer cerebrolysin as part of supervised protocols. Cancer-adjacent research: cerebrolysin's neurotrophic properties have drawn preclinical research interest in the context of chemotherapy-induced cognitive impairment (chemobrain), where neuroprotection during and after oncology treatment is a research priority. Autism spectrum disorder research: small controlled trials from Eastern European groups have evaluated cerebrolysin for speech and behavioral development in children with ASD, with mixed results; this remains an exploratory research area with no established clinical consensus. Stroke rehabilitation remains cerebrolysin's strongest evidence base, with multiple controlled trials evaluating cognitive and functional recovery in post-stroke patients.

Tuftsin-derived heptapeptide with structural modifications that resist enzymatic degradation. Modulates GABA-A receptor complex, increases enkephalin levels in limbic system, and influences serotonin metabolism.

N-Acetyl-Selank is an acetylated derivative of selank (TKPRPGP), a synthetic heptapeptide anxiolytic developed from a tuftsin-based sequence; N-acetylation at the N-terminus is proposed to improve resistance to enzymatic degradation and potentially alter blood-brain barrier permeability relative to the parent compound, with the expectation of enhanced CNS bioavailability and duration of action. The pharmacological rationale derives from the parent compound selank, which acts through GABAergic, serotonergic, and enkephalinergic pathways to produce anxiolytic and nootropic effects in preclinical models and limited Russian human clinical studies; N-acetyl-selank is presumed to retain similar receptor interactions with modified pharmacokinetics. No publications indexed in PubMed specifically examine N-acetyl-selank as a distinct compound; no human clinical trials, independent preclinical studies, or pharmacokinetic comparisons with the parent selank exist in the indexed scientific literature, representing a complete absence of specific evidence for this analog beyond its structural modification. N-Acetyl-Selank has no FDA approval and no approved indication in any jurisdiction; it is available through research chemical suppliers as a purported improvement on selank, but its pharmacological properties, safety profile, and clinical utility in humans are entirely uncharacterized as a distinct compound.